However, it was found that baseline circulating ADCC-capable immune cells that are functionally suppressed by PD-1 are potentially indicative of HER2+ breast cancer patients that will not achieve optimal benefit from neo-adjuvant treatment (Fig. 6b). Here, ERBB2 is linked to breast carcinoma.